“The markets for microarrays, public-domain clones, transgenics, and contract-sequencing services … have been marked by increasing competition and margin erosion that appear to be a permanent trend.”
— Roy Whitfield, CEO of Incyte, announcing that the company is getting rid of its custom genomics program and laying off 400 employees
Find “Incyte to Slash 400 Jobs, Jettisons Custom Genomics Platform” by searching: Incyte
Wish on a Star
Celera Genomics has turned its gaze heavenward in its quest for more powerful bioinformatics. It has inked a deal with the Association of Universities for Research in Astronomy to license a software package originally designed to process data collected by the Hubble telescope.
Find “Celera Licenses Informatics Software Designed for Hubble Telescope” by searching: Hubble
Burying the Hatchet
Hyseq and Affymetrix announced that they have agreed to dismiss all pending suits in the US District Court, to cease their involvement in pending patent interference proceedings before the US Patent and Trade Office, and to form a joint venture. Also, Hyseq said it would use the proceeds of the settlement to fund the launch of a new subsidiary, Callida Genomics, that will develop and commercialize its sequencing-by-hybridization technology.
Find “In Weird Turn of Events, Hyseq and Affy Settle Suit and Form Joint Venture” by searching: Hyseq
Going, Going, Gone?
Invitrogen is exploring the possibility of acquiring Incyte Genomics, a source said. The company is interested in acquiring the genomics data provider but is waiting to act until the price is right. Industry analysts said that Incyte and Invitrogen likely began speaking six months ago.
Find “Invitrogen Believed to Be Exploring Acquisition of Incyte Genomics” by searching: Invitrogen
Open Sesame Oligos
While would-be competitors Incyte and Corning hand out pink slips, Affymetrix has been having a red-letter month. With a solid third quarter and major deals with Motorola and Hyseq, the company has opted to give customers the sequences of its oligonucleotide probes through its NetAffx Internet portal.
Find “Affymetrix on a Roll, Plans to Reveal Oligo Probe Sequences” by searching: oligo
Since its first demo a year ago, Lincoln Stein’s distributed sequence annotation system has rapidly gained support throughout the bioinformatics community as an effective way to allow third-party genomic annotators to integrate and view their annotations along with those of other researchers. But popularity has its downside. “People expect DAS to do more than it was really designed to do,” Stein said.
Find “As Servers Multiply, Stein Sees Expectations for Distributed Annotation System Grow” by searching: Stein
A patent and licensing dispute between Biosite and Xoma has disrupted a collaboration between Large Scale Biology Corporation and Biosite, and threatens to derail LSBC’s efforts to develop protein microarrays. Company officials were tight-lipped about what course of action LSBC might take.
Find “LSBC Suspends Protein Delivery to Biosite; Might Seek Other Partner” by searching: LSBC